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Immunosuppressive Effect of FK-506 
on In Vitro Lymphocyte Alloactivation: 
Synergism With Cyclosporine A 
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RECENT STUDIES have described a new potent immunosuppressive drug FK-506 
(FK) that induces considerable prolongation 
of allograft survival.'·) This drug is isolated 
from Streptomyces tsukubaensis. has a 
molecular weight of 822 daltons, and is struc-
turally different from cyclosporine A (CsA). 
In vitro investigations have demonstrated a 
strong inhibitory effect on lymphocyte activa-
tion that appears to be mediated by blocking 
of interleukin 2 (IL-2) release.4 Our studies 
have extended these findings by showing that 
FK inhibits secondary proliferation of allo-
reactive T lymphocytes generated from mixed 
lymphocyte reaction (MLR) cultures or pro-
pagated from organ transplant biopsy speci-
mens with cellular infiltrates.s The in vitro 
immunosuppressive effect of FK is generally 
several hundredfold greater than that of CsA. 
On the other hand, FK does not inhibit sec-
ondary proliferation of activated T cells stim-
ulated by IL-2. 
With respect to the possibility that FK 
could be used together with CsA as an immu-
nosuppressive drug regimen to prolong allo-
graft survival, we studied in vitro effects of 
low doses of these drug combinations on lym-
phocyte proliferation. The results demon-
strate synergism between FK and CsA in their 
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inhibition of both primary lymphocyte alloac-
tivation and secondary proliferation of allo-
reactive T cells. This in vitro synergism may 
have clinical application in that low doses of 
FK and CsA .:ombinations may be effective in 
increasing transplant survival. 
MATERIALS AND METHODS 
M LR-Induced Proliferation 
Human peripheral blood lymphocytes were isolated 
from heparinized blood by Ficoll-Hypaque density gra-
dient centrifugation. Undirectional MLR cultures were 
set up with 105 responder and 105 irradiated (2,000 R) 
stimulator cells in a volume of 200 ItL of tissue culture 
medium (TCM) supplemented with 10% human serum 
and incubated for six days. During the final 20 hours of 
incubation, each culture was labeled with I ItCi of 
lH-thymidine. The cultures were harvested and counted 
in a liquid scintillation counter. 
Primed Lymphocyte Test 
Alloreactive lymphocyte cultures were propagated 
from human heart and liver transplant biopsy specimens 
in the presence of IL-2 as previously reported.·" Second-
ary proliferation of alloreactive T cells was assessed in a 
three-day primed lymphocyt~ test (PLT) whereby 10' 
responder cells were incubated with lOS irradiated (2,000 
R) stimulator cells. Lymphocyte proliferation was deter-
mined by lH-thymidine incorporation as described ear-
lier. 
Drug Sources 
FK was supplied by the Fujisawa Pharmaceutical Co, 
Ltd, Osaka, Japan. This drug was received as a crystalline 
powder, and before use it was dissolved in methanol and 
further diluted in TCM. CsA was obtained from Sandoz, 
Inc, Hanover, NJ. It was dissolved in ethanol and further 
diluted in TCM to various concentrations. 
Dose Effects of FK and CsA on Lymphocyte 
Proliferation 
The inhibitory effects of FK and CsA on MLR reactiv-
ity and PL T response of alloreactive lymphOCytes were 
measured at different concentrations of drugs ranging 
from 0.06 to 500 ng/mL. The results were expressed as 
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IMMUNOSUPPRESSIVE EFFECT OF FK-506 
percent inhibition by using the following formula: percent 
inhibition - I - (cpm with drugs x 100/cpm without 
drugs). 
Pretreatment of Alloreactive T Cells 
With CsA and FK 
Heart biopsy specimen-propagated alloreactive T cells 
were cultured with 20 IU /mL of recombinant IL-2 with 
and without 10 Ilg/mL of CsA or various concentrations 
of FK (I Ilg/mL, 0.1 Ilg/mL, and 0.01 Ilg/mL). After 
four days of incubation, the cell cultures were washed and 
tested for cell viability. The cells were then tested for 
donor-specific PL T reactivity by incubating 10· cells with 
!O5 irradiated stimulators for three days. Control cultures 
were tested for proliferation in the presence of IL-2. In 
addition, these pretreated cells were tested for their 
sensitivity to FK and CsA in PL T assays. 
RESULTS 
Synergism Between FK and CsA 
in Inhibition of Lymphocyte Activation 
Studies on lymphocyte proliferation in pri-
mary MLR have previously shown that inhibi-
tion was observed at concentrations of FK that 
were several hundredfold lower than those of 
CSA.4 An example of the differences between 
FK and CsA is shown in upper part of Fig 1. It 
may be seen that significant inhibition of 
greater than 75% was observed at concentra-
tions of 1 ng FKjmL and 500 ng CsAjmL. 
The bottom part of Fig 1 illustrates that 
combinations of 0.1 ngjmL of FK and 10 
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Fig 1. Synergism between FK and CsA inhibition of 
MLR response. 
ngjmL or 1 ngjmL of CsA induced consider- whereas at these concentrations each of these 
able MLR inhibition, whereas at these low drugs alone had no significant effect. 
concentrations neither drug had any signifi- These findings demonstrate that at very low 
cant effect. :~-«-concentrations FK and CsA have synergistic 
Another example of the synergism between inhibitory effects on both primary and second-
low doses of FK and CsA is shown in Fig 2, ary T lymphocyte activation. 
which depicts the results of studies on donor-
specific secondary proliferation of alloacti-
vated T lymphocytes propagated from liver 
transplant biopsy material. The upper part of 
Fig 2 shows that the inhibition of the PLT 
response of these cells by FK was effective at a 
400-fold lower concentration than that of 
CsA. The lower part of Fig 2 demonstrates 
that a combination of low doses of FK and 
CsA exerted significant inhibitory effects, 
Effect of FK and CsA Treatment 
of Alloreactive T Cells 
Studies were designed to determine 
whether pretreatment of alloactivated T cells 
with FK or CsA affected subsequent second-
ary donor-specific proliferation. Because 
these drugs have no effect on IL-2-induced 
proliferation of activated T cells (Table 1), 
experiments were set up whereby heart biopsy 
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Fig 2. Synergism between FK and CsA inhibition of 
the PL T response of liver biopsy specimen-propagated 
lymphocytes. 
material-grown lymphocytes were expanded 
with IL-2 in the presence of FK or CsA at 
various concentrations. After four days in 
culture, these expanded alloreactive T cell 
cultures were washed and then restimulated 
with donor cells in three-day PLT assays. The 
Table 1. Lack of Inhibitory Effect of FK and CsA 
on IL-2-lnduced Proliferation of Alloreactive 
T Cell Clone DB29 
Dose IL-2 Response 
Drug (sLg/mL) (cpm) 
Nothing None 235 
IL-2 None 5.296 
IL-2 + FR 0.1 5.085 
IL-2 + CsA 5,718 
The MLR-generated alloreactive T cell clone 0829 is 
specific for a DQwl-associated cellular determinant. 
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results shown in Table 2 demonstrate that 
pretreatment with FK at 1 J.lg/mL caused 
significant inhibition of PL T stimulation four 
days later but had no effect on IL-2-induced 
proliferation. On the other hand. pretreat-
ment with CsA or lower doses of FK had no 
significant effect on the subsequent PL T 
response. 
Effect of FK and CsA Pretreatment on Drug 
Sensitivity of Alloreactive T Cells 
The PL T response of pretreated cells was 
also tested for its susceptibility to inhibition 
by CsA (Fig 3). Pretreatment of IL-2-
expanded heart transplant biopsy specimen-
grown lymphocytes with 10 J.lg/mL CsA 
yielded cells whose PL T reactivity had essen-
tially the same CsA sensitivity as control cells 
that were cultured without drugs. On the 
other hand, pretreatment with FK at 0.1 
J.lg/mL yielded cell cultures whose PLT reac-
tivity was considerably more sensitive to CsA, 
and strong inhibition was observed at concen-
trations as low as 0.05 J.lg/mL of CsA. It may 
be seen in Fig 3 that pretreatment with FK at 
0.01 J.lg/mL also yielded cells with increased 
CsA sensitivity of their PLT responses. 
Further studies were conducted to deter-
mine whether pretreatment with CsA or FK 
leads to an increased sensitivity of alloacti-
vated T cells to FK (Table 3). Heart trans-
plant biopsy specimen-grown lymphocytes 
expanded with IL-2 in the presence of 10 
J.lg/mL CsA showed similar FK sensitivity of 
their donor-specific PL T response as control 
Table 2. Effect of Pretreatment With FK or CsA on the 
IL-2 Responsiveness and Donor-Specific Reactivity of 
Lymphocytes Propagated From Heart Biopsy Material 
Pretreatment 
Dose Proliferation Responses (cpm) 
Drug (,,/mL) Background IL-2 PLT 
Control None 534 22,056 66;447 
FK 1 455 30,834 8,126 
FK 0.1 449 29,806 81,242 
FK 0.01 436 30,638 102.045 
CsA 10 351 15,535 57,889 
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Fig 3. Increased CsA sensitivity of heart biopsy specimen-grown lymphocytes pretreated with FK. 
cell cultures grown without drugs. On the 
other hand, pretreatment with low doses of 
FK yielded cells that showed increased sensi-
tivity to FK, although the effect was not as 
impressive as the enhanced sensitivity to CsA 
shown in Fig 3. 
DISCUSSION 
These findings demonstrate synergism 
between the immune suppressive effects of 
low doses of FK and CsA in two types of in 
vitro assays. The first deals with a simulta-
neous incubation of these drugs during pri-
mary or secondary alloactivation of human T 
lymphocytes. The other assay shows syner-
gism through sequential exposure of alloreac-
tive lymphocytes to FK followed by CsA. The 
synergism between FK and CsA suggests that 
low-dose combinations of these drugs may be 
effective in prolonging allograft survival. 
Indeed, our experience with cardiac allografts 
in rats have shown a strong immunosuppres-
sive effect of combinations of FK and CsA.2 
An advantage of using combinations of low 
doses of FK and CsA to prolong transplant 
survival is that there would be a reduction of 
undesirable side effects of these drugs. For 
instance, the nephrotoxicity of CsA in trans-
Table 3. Inhibition of PL T Reactivity of Pretreated Heart Biopsy Specimen-Grown Lymphocyte Cultures in the 
Presence of Various Doses of FK 
FK Percent Inhibition of PI. T Response HB Cultures· 
(jtg/mLI Control CsA (10 I'g/mLl FK (0.1 jtg/mLI FK (0.01 I'g/mll 
0.1 95 94 95 95 
0.01 93 93 93 94 
0.001 86 89 90 87 
0.00025 0 0 63 21 
0.00012 0 0 51 13 
-Lymphocytes propagated from heart biopsy (HB) material were cultured with IL-2 in the presence of drugs (CsA and FK) for 
four days befae the PL T inhibition test. 
44 
plant patients could be markedly reduced if 
lower doses are used in combination. perhaps 
with low doses of FK. 
Little is understood about the mechanism 
of the synergism between FK and CsA. For 
both drugs. the inhibitory effect of lympho-
cyte proliferation is mediated by blockage of 
IL-2 release (Kino et al4 and unpublished 
data). On the other hand. neither drug causes 
significant inhibition of IL-2-induced prolif-
eration. The presence of IL-2 receptors on 
activated T cells is required for this prolifera-
tion. The appearance of IL-2 receptors on 
MLR-activated cells has been shown to be 
inhibited by FK.4 This would mean that such 
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cells would be less responsive to the stimulat-
ing effects of lL-2. However. our current 
studies do not support this notion because FK 
pretreatment of alloreactive T cells expanded 
with lL-2 did not render these cells less 
responsive to subsequent IL-2 stimulation, 
although their PL T responsiveness was 
impaired. Recent studies at our institution 
have shown that FK pretreatment of lympho-
cytes increases the binding of CSA.8 These 
findings suggest that the synergism between 
FK and CsA might be related to lymphocyte 
membrane binding-of these drugs. Studies are 
currently in progress to obtain a better under-
standing of the mechanism of this synergism. 
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